Oncotelic's IV Sapu003 Shows 67-Fold Reduction in GI Drug Accumulation Compared to Oral Everolimus

Oncotelic Therapeutics, a 45% owner of the Sapu Nano joint venture, has released new pharmacokinetic data demonstrating that its intravenous formulation of everolimus, called Sapu003, dramatically reduces gastrointestinal drug accumulation compared to oral administration. The findings show oral everolimus creates extreme gut exposure—reaching up to 2,448 times plasma levels in the stomach—while intravenous Sapu003 limits gastrointestinal tissue levels to just 36–48 times plasma levels, representing reductions of up to 67-fold.

The company stated this significant reduction in gastrointestinal exposure may improve patient tolerability while maintaining the drug's intrinsic metabolic profile and providing more consistent systemic exposure. Everolimus is an mTOR inhibitor used in cancer treatment, but its oral administration often leads to gastrointestinal side effects that can limit patient compliance and treatment effectiveness.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications. The company's CEO, Dr. Vuong Trieu, has filed more than 150 patent applications and holds 39 issued U.S. patents, contributing to the company's robust portfolio of inventions. Beyond its internal programs, Oncotelic also licenses and codevelops drug candidates through joint ventures, including its 45% ownership of GMP Bio.

The implications of this development are significant for cancer patients who struggle with the gastrointestinal side effects of oral everolimus. By reducing gut exposure by up to 67 times, Sapu003 could potentially allow patients to continue treatment without the debilitating gastrointestinal issues that often accompany oral administration. This could lead to better treatment adherence, more consistent therapeutic levels in the bloodstream, and ultimately improved treatment outcomes.

For the pharmaceutical industry, this represents an important advancement in drug delivery technology. The ability to maintain a drug's therapeutic effectiveness while dramatically reducing side effects through improved formulation and delivery methods addresses a critical challenge in oncology treatment. The full press release detailing these findings is available at https://ibn.fm/dVPuX.

The latest news and updates relating to Oncotelic Therapeutics are available in the company's newsroom at https://ibn.fm/OTLC. BioMedWire, which distributed this announcement, is a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences developments, operating as part of the Dynamic Brand Portfolio at IBN. More information about BioMedWire is available at https://www.BioMedWire.com, with full terms of use and disclaimers at https://www.BioMedWire.com/Disclaimer.